David Volkin

Lack of stability often limits the use of biopharmaceuticals and vaccines (e.g., proteins, DNA/RNA, virus-like-particles, and viruses) as human medicines.  Loss of potency can occur during manufacturing, storage, or administration.  Our research objective is to understand the changes in physicochemical properties that accompany the loss of biological activity, and to develop new analytical techniques to monitor these changes at the molecular level.  A detailed understanding of the causes and molecular mechanisms of instability will guide the design of more potent and stable biopharmaceutical and vaccine dosage forms  As co-founder of the Vaccine Analytics and Formulation Center (VAFC) at The University of Kansas, our group collaborates extensively with partners (non-profits, small/large biopharma/vaccine companies, and academia) on analytical characterization and formulation development projects to facilitate novel candidates entering clinical trials with an emphasis on new candidates for use in the developing world.. 

One of 34 U.S. public institutions in the prestigious Association of American Universities
44 nationally ranked graduate programs.
—U.S. News & World Report
Top 50 nationwide for size of library collection.
5th nationwide for service to veterans —"Best for Vets: Colleges," Military Times
KU Today

Our research projects ranging from traditional pharmaceutics to biotechnology. 

Learn more here.